<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695305</url>
  </required_header>
  <id_info>
    <org_study_id>LP2105521</org_study_id>
    <nct_id>NCT00695305</nct_id>
  </id_info>
  <brief_title>An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks</brief_title>
  <official_title>A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study in patients with atherosclerosis to assess safety, effect and PK of rilapladib vs.
      placebo over 12 weeks of dosing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study LP2105521 is a randomized, double-blind, placebo-controlled, parallel-group study to
      examine the safety, tolerability, and effects of rilapladib on plasma Lp-PLA2 activity,
      plaque inflammation, and PAF (if feasible). Subjects will receive placebo or rilapladib once
      daily for 12 weeks. The study will be conducted in subjects with established atherosclerosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety from AE reporting, vital signs, clinical labs, ECGs, slit lamp eye exams and electron microscopy of peripheral blood lymphocytes.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>LP-PLA2 activity;</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in mean standard values of 18 FDG uptake as assessed by PET and MRI imaging</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimation of PK parameters (such as: apparent volume of distribution, apparent clearance, etc.) of rilapladib and their associated variability, appropriate to the final model</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of PK/PD parameters (such as: IC50, Eo) and their associated variability, appropriate to the final model</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour ambulatory blood pressure monitoring</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAF levels in human plasma as feasible</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo to match</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rilapladib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rilapladib</intervention_name>
    <description>250 mg oral dose once daily</description>
    <arm_group_label>rilapladib</arm_group_label>
    <other_name>SB-659032</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F Fluorodeoxylucose (FDG)-PET</intervention_name>
    <description>FDG-PET</description>
    <arm_group_label>rilapladib</arm_group_label>
    <other_name>FDG marker</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving written informed consent and able to understand and comply with
             protocol requirements, instructions and protocol-stated restrictions.

          -  Male or female, aged 50 to 80 years inclusive, at screening.

          -  Females must be of non-childbearing potential

          -  Body weight ≥ 50 kg and BMI within the range 19-35 kg/m2

          -  Documented atherosclerotic vascular disease (e.g. prior MI, prior revascularization,
             peripheral arterial disease, carotid disease, or cerebrovascular disease) and
             clinically stable for at least 6 months

          -  If diabetic, have well controlled diabetes, defined for the purpose of this study as
             HbA1c ≤8% or FPG ≤200 mg/dL

          -  Evidence of plaque inflammation [carotid artery or ascending aorta plaque inflammation
             defined as a tissue to background ratio (TBR) ≥ 1.6]

          -  On a stable dose of a statin for 3 months prior to screening with no evidence of
             statin intolerance

        Exclusion Criteria:

          -  Recent (i.e., &lt;6 months from Screening Visit) CV event defined as ST-elevation MI or
             non-ST-elevation MI, confirmed by cardiac enzyme elevation and ECG changes, coronary
             revascularization (PCI or CABG), stroke of any etiology, resuscitated sudden death,
             prior carotid surgery or stenting procedure

          -  Evidence of clinical instability or abnormal clinical laboratory findings prior to
             randomization that, in the opinion of the Investigator, makes the subject unsuitable
             for the study.

          -  Exposure to substantial radiation within the past 12 months

          -  Planned cardiac surgery (e.g., CABG, valve repair or replacement, or aneurysmectomy),
             PCI or major non-cardiac surgery within the study period

          -  Current inadequately controlled hypertension (blood pressure ≥160 mmHg systolic or
             ≥100 mmHg diastolic) on a stable dose of anti-hypertensive medication

          -  Diabetics taking injectable insulin at screening

          -  Serum triglycerides &gt;400 mg/dL, LDLc &gt;130 mg/dL

          -  Recent (&lt;1 month) or ongoing acute infection.

          -  History of chronic inflammatory disease

          -  Recently received (&lt;1 month) or currently receiving oral or injectable
             corticosteroids, or regular use of nasal, inhaled or topical corticosteroids.

          -  Subjects who will commence, or who are likely to commence regular treatment with oral,
             non-steroidal anti-inflammatory drugs (NSAIDs) from screening until study completion

          -  Currently receiving oral or injectable potent CYP3A4 inhibitor(s)

          -  History of chronic viral hepatitis or other chronic hepatic disorders; or ALT or AST
             &gt;1.5 x ULN, or alkaline phosphatase or total bilirubin &gt;1.5 x ULN of laboratory
             reference range at Screen

          -  Renal impairment with serum creatinine &gt;2.0 mg/dl or history of kidney transplant or
             status post nephrectomy.

          -  History of myopathy or inflammatory muscle disease, or elevated total CPK at screening

          -  History of severe heart failure defined as NYHA class III or IV or those with known
             severe left ventricular dysfunction (ejection fraction&lt;30%) regardless of symptomatic
             status

          -  History of adult asthma (or reactive airway disease) manifested by bronchospasm in the
             past 6 months, or currently taking regular anti-asthmatic medication(s)

          -  History of anaphylaxis, anaphylactoid (resembling anaphylaxis) reactions or severe
             allergic responses

          -  History of malignancy within the past 2 years.

          -  A history of glaucoma or any other findings in the baseline eye exam

          -  Current life-threatening condition other than vascular disease that may prevent a
             subject from completing the study

          -  QTc interval ≥450msec at screening or ≥480 msec for subjects with bundle branch block

          -  History of drug abuse within the past 6 months

          -  Previous exposure to rilapladib.

          -  Contraindication to MRI scanning

          -  Use of an investigational drug within 30 days or 5 half-lives (whichever is the
             longer) preceding the first dose of study medication

          -  Any other subject the Investigator deems unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>01830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linden</city>
        <state>New Jersey</state>
        <zip>07036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Massapequa</city>
        <state>New York</state>
        <zip>11758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2008</study_first_submitted>
  <study_first_submitted_qc>June 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2008</study_first_posted>
  <disposition_first_submitted>March 17, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>March 17, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 28, 2011</disposition_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rilapladib,</keyword>
  <keyword>Lp-PLA2,</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>SB-659032,</keyword>
  <keyword>FDG-PET,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>LP2105521</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>LP2105521</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>LP2105521</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>LP2105521</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>LP2105521</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>LP2105521</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>LP2105521</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <pending_results>
    <submitted>July 25, 2017</submitted>
    <returned>August 25, 2017</returned>
    <submitted>September 14, 2017</submitted>
    <returned>October 13, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

